Rapid and Efficient Therapeutic Antibody Discovery Using AvantGen’s Germliner™ Library Collection
CD16a is a challenging target for antibody discovery due to potential cross reactivity with CD16b, a surface marker with 98.5% sequence identity and a counterproductive regulatory function.
This white paper shows how a panel of anti-CD16a monoclonal antibodies with highly developable properties and no cross reactivity were generated in only 4 months with a yeast display library of over 100 billion clones, rationally designed to remove problematic antibody sequences before discovery even starts.
Read the paper to learn:
- The limitations of antibody discovery by immunization and phage display.
- Why these limitations lead to years-long development cycles.
- How yeast libraries and rational design can cut that timeframe dramatically.
- How AvantGen’s Germliner platforms can narrow 1011 potential antibodies to a panel of highly developable candidates in months.